Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00503906
Status:
COMPLETED
Last Update Posted:
2017-05-12
First Post:
2007-07-17
Brief Title:
Abraxane Avastin and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
Sponsor:
University of Miami
Organization:
University of Miami
Study Overview
Official Title:
A Phase II Study of Abraxane Avastin and Gemcitabine for First Line Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators hypothesize that the combination of Gemzar Abraxane and Avastin will increase the progression-free survival PFS in patients with first line metastatic breast cancer and in patients who received neoadjuvant andor adjuvant chemotherapy present with definable metastatic disease 6 or more months after primary treatment
Detailed Description:
This is a phase 2 single arm study Participants will be treated with combination Gemzar Abraxane and Avastin therapy until disease progression Each treatment cycle is 28 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SCCC-2006081 | OTHER | University of Miami Sylvester Comprehensive Cancer Center | None |